The study's results indicate that both the 10mg and 25mg doses of brensocatib have shown a meaningful reduction in the rate of pulmonary exacerbations compared to placebo, with the 25mg dose exhibiting additional benefits in lung function and quality of life measures. These findings suggest that brensocatib could become a key long-term asset for Insmed, potentially addressing a multi-billion dollar market and expanding into other neutrophil-mediated diseases. Furthermore, the detailed data released shows that the 25mg dose notably slowed the decline in forced vital capacity (FVC) and improved bronchiectasis symptoms, providing a statistically significant difference from placebo.